XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
XTL Biopharmaceuticals Ltd. is set to hold its Annual and Extraordinary General Meeting on July 22, 2024, to discuss crucial corporate matters including the previous year’s auditor’s report, re-appointing auditors, re-electing Board members, and approving the acquisition of The Social Proxy Ltd. Shareholders as of June 24, 2024, will be able to vote in person or by proxy, with the Board recommending a vote ‘FOR’ on all agenda items. Key decisions include the issuance of shares and payment for the acquisition, alongside electing new directors contingent upon the deal’s completion.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.